Marktanalyse - Graves' Ophthalmopathy - Pipeline Review, H2 2016

Global Markets Direct
12.2016
39 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Graves' Ophthalmopathy - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy — Pipeline Review, H2 2016, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 2 and 1 respectively.Graves' Ophthalmopathy.

Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Graves' Ophthalmopathy Overview 6

Therapeutics Development 7

Pipeline Products for Graves' Ophthalmopathy - Overview 7

Graves' Ophthalmopathy - Therapeutics under Development by Companies 8

Graves' Ophthalmopathy - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Graves' Ophthalmopathy - Products under Development by Companies 11

Graves' Ophthalmopathy - Companies Involved in Therapeutics Development 12

Genmab A/S 12

Neothetics Inc 13

Novartis AG 14

Yuhan Corp 15

Graves' Ophthalmopathy - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Combination Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

(fluticasone propionate + salmeterol xinafoate) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

pasireotide ER - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Synthetic Peptides for Graves' Orbitopathy - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

teprotumumab - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

YH-BIO - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

YH-NCE3 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Graves' Ophthalmopathy - Dormant Projects 36

Graves' Ophthalmopathy - Product Development Milestones 37

Featured News & Press Releases 37

Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease 37

Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39





List of Tables

Number of Products under Development for Graves' Ophthalmopathy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Graves' Ophthalmopathy - Pipeline by Genmab A/S, H2 2016 12

Graves' Ophthalmopathy - Pipeline by Neothetics Inc, H2 2016 13

Graves' Ophthalmopathy - Pipeline by Novartis AG, H2 2016 14

Graves' Ophthalmopathy - Pipeline by Yuhan Corp, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Assessment by Combination Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Graves' Ophthalmopathy - Dormant Projects, H2 2016 36





List of Figures

Number of Products under Development for Graves' Ophthalmopathy, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus